Effects of denosumab treatment on bone mineral density and joint destruction in patients with rheumatoid arthritis
Effects of denosumab treatment on bone mineral density and joint destruction in patients with rheumatoid arthritis
复制标题
DOI：
10.1007/s00774-017-0848-1
复制
发表时间：
2018-07-01
影响因子：
3.3
通讯作者：
Momohara, Shigeki
中科院分区：
文献类型：
--
作者：
Mochizuki, Takeshi;Yano, Koichiro;Momohara, Shigeki
我们的目的是研究denosumab治疗类风湿性关节炎（RA）的疗效。这项研究招募了70名RA患者，他们在基线和6个月时接受了denosumab 60mg皮下注射。采用双能x线骨密度仪测量腰椎、全髋关节、股骨颈和手部的骨密度。从基线前12个月和基线后12个月的总修正夏普评分（mTSS）、侵蚀（EN）评分和关节间隙缩小评分的变化。12个月时，腰椎、全髋关节、股骨颈和手部的骨密度平均值分别显著增加了7.3、4.7、3.9和5.4%。与12个月前的基线值相比，12个月后mTSS值（1.13 vs. 0.59, p = 0.002）和EN评分（0.40 vs. 0.07, p < 0.001）显著降低。现有联合denosumab治疗RA患者骨质疏松和关节破坏可能有效。
We aimed to investigate the efficacy of denosumab for rheumatoid arthritis (RA). This study enrolled 70 RA patients who received denosumab 60 mg subcutaneous injection at baseline and at 6 months. Bone mineral densities (BMD) of the lumbar spine, total hip, femoral neck, and hand were measured by dual energy X-ray absorptiometry. Changes in total modified Sharp score (mTSS), erosion (EN) score, and joint space narrowing score at baseline from 12 months before and at 12 months from baseline. The mean values of BMD of the lumbar spine, total hip, femoral neck, and hand significantly increased by 7.3, 4.7, 3.9, and 5.4%, respectively, at 12 months. At 12 months from baseline, there were significant decreases in the values of mTSS (1.13 vs. 0.59; p = 0.002) and EN score (0.40 vs. 0.07; p < 0.001), compared with the values at baseline from 12 months before. The existing combined modality therapy with denosumab might be effective for osteoporosis and joint destruction in patients with RA.